Karos, Daria

Karos, Daria was paid $620K by Medicaid between Mar 2018 and Mar 2023, across 20 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 33% of everything it billed.

33Billing provider infoKAROS, DARIA
FITCHBURG, MA 01420

33aNPI1710935416assigned 05/04/2006

33bProvider typePediatrics Physician

28Total paid$620K

24GClaims8,949

24DCodes billed20

24AFirst – last monthMar 2018 – Mar 2023

Compared with peers

Next to other Pediatrics Physician providers in Massachusetts

Rank by total paid#126 of 1,273

Median peer was paid$24K

This provider vs. median26×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	687	$72K
2019	1,415	$71K
2020	1,422	$78K
2021	2,445	$178K
2022	2,535	$185K
2023	445	$36K

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
99214	Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity	33%	1,197	952	$207K
99213	Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity	26%	2,382	1,708	$160K
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	16%	2,087	961	$99K
G0480	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed	15%	1,587	796	$95K
90460	Immunization administration through 18 years of age via any route, first or only component	2.6%	439	223	$16K
90471	Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine	1.7%	344	341	$10K
87635	Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe	1.3%	106	103	$8K
99188		<1%	135	135	$5K
99393	Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years)	<1%	29	29	$5K
96110	Developmental screening, with scoring and documentation, per standardized instrument	<1%	227	227	$4K
99392	Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years)	<1%	25	25	$3K
90472	Immunization administration, each additional vaccine (list separately)	<1%	75	75	$2K

8 more codes

99391	Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year)	<1%	13	$1K
99051		<1%	42	$1K
96127		<1%	65	$956.35
99211	Office or other outpatient visit for the evaluation and management of an established patient, minimal severity	<1%	60	$924.60
87880	Infectious agent antigen detection by immunoassay; Streptococcus, group A	<1%	27	$548.57
90461		<1%	44	$498.08
81025		<1%	53	$346.80
92551		<1%	12	$152.76

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.